ATE506961T1 - Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen - Google Patents

Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen

Info

Publication number
ATE506961T1
ATE506961T1 AT06717966T AT06717966T ATE506961T1 AT E506961 T1 ATE506961 T1 AT E506961T1 AT 06717966 T AT06717966 T AT 06717966T AT 06717966 T AT06717966 T AT 06717966T AT E506961 T1 ATE506961 T1 AT E506961T1
Authority
AT
Austria
Prior art keywords
ccn3
diseases
treatment
protein
diagnosis
Prior art date
Application number
AT06717966T
Other languages
English (en)
Inventor
Bruce Riser
Bernard Perbal
Original Assignee
Univ Rosalind Franklin Medicine & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rosalind Franklin Medicine & Science filed Critical Univ Rosalind Franklin Medicine & Science
Application granted granted Critical
Publication of ATE506961T1 publication Critical patent/ATE506961T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06717966T 2005-01-10 2006-01-10 Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen ATE506961T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64272805P 2005-01-10 2005-01-10
PCT/US2006/000833 WO2006074452A2 (en) 2005-01-10 2006-01-10 Regulation of ccn2 by ccn3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases

Publications (1)

Publication Number Publication Date
ATE506961T1 true ATE506961T1 (de) 2011-05-15

Family

ID=36648253

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06717966T ATE506961T1 (de) 2005-01-10 2006-01-10 Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen

Country Status (10)

Country Link
EP (1) EP1841316B1 (de)
JP (1) JP4834677B2 (de)
AT (1) ATE506961T1 (de)
AU (1) AU2006203851B8 (de)
CA (1) CA2597794A1 (de)
DE (1) DE602006021534D1 (de)
DK (1) DK1841316T3 (de)
ES (1) ES2395260T3 (de)
PL (1) PL1841316T3 (de)
WO (1) WO2006074452A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0618748D0 (en) * 2006-09-22 2006-11-01 Univ Belfast Peptide
WO2010048347A2 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5939584B2 (ja) * 2010-04-02 2016-06-22 ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス 治療用ｃｃｎ３ペプチドおよびそれらの類似体
US9114112B2 (en) * 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
WO2011134063A1 (en) * 2010-04-26 2011-11-03 UNIVERSITé LAVAL Ccn3 and uses thereof against metabolic syndrome- associated disorders
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia
EP3711772A1 (de) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Rekombinante proteine und fusionsproteine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
FR2825928B1 (fr) * 2001-06-18 2004-04-02 Ecole Norm Superieure Cachan Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine
EP1382347A1 (de) * 2002-07-17 2004-01-21 UNIVERSITE PARIS 7 - Denis DIDEROT Verwendung von Mitgliedern der CCN-Protein-Familie zur Behandlung von Erkrankungen im Zusammenhang mit verändertem Kalzium und/oder Natrium-Flux
WO2004090109A2 (en) * 2003-03-31 2004-10-21 Munin Corporation Ccn3 compositions and methods
CA2582224A1 (en) * 2004-09-28 2006-04-06 Lester F. Lau Compositions and methods for modulating tissue regeneration and chemotactic responses

Also Published As

Publication number Publication date
EP1841316A2 (de) 2007-10-10
EP1841316B1 (de) 2011-04-27
EP1841316A4 (de) 2008-07-09
WO2006074452A3 (en) 2006-11-16
AU2006203851B8 (en) 2012-11-15
DE602006021534D1 (de) 2011-06-09
JP4834677B2 (ja) 2011-12-14
CA2597794A1 (en) 2006-07-13
AU2006203851B2 (en) 2012-04-12
WO2006074452A2 (en) 2006-07-13
PL1841316T3 (pl) 2011-09-30
JP2008526890A (ja) 2008-07-24
ES2395260T3 (es) 2013-02-11
DK1841316T3 (da) 2011-08-08
AU2006203851A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
EA200700886A1 (ru) Соединение тиадиазола и его применение
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
PH12015500297A1 (en) Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
EP2175879A4 (de) Behandlung von erkrankungen im zusammenhang mit prion-protein
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
EP1978362A3 (de) Cross-Beta-Struktur mit Amyloid-bindenden Proteinen und Verfahren für den Nachweis einer Cross-Beta-Struktur, zur Modulation der Fibrillenbildung von Cross-Beta-Strukturen und Cross-Beta-Struktur-vermittelter Toxizität
ATE506961T1 (de) Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
MX2009005550A (es) Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica.
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
ATE410415T1 (de) Neue verbindungen
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1841316

Country of ref document: EP